FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011396543> ?p ?o ?g. }

• W2011396543 endingPage "355" @default.
• W2011396543 startingPage "347" @default.
• W2011396543 abstract "Two different hepatoma cell lines were incubated for 48 h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy. We observed that cisplatin and paclitaxel induced cytotoxicity, but significant differences between both cell lines, were found only in the case of paclitaxel. At 48 h, apoptosis was clearly present in Hep3B cells treated with cisplatin and HepG2 cells treated with paclitaxel. 5-FU induced cytotoxicity in both cell lines but only at higher concentrations than the other two drugs, triggering apoptosis and necrosis in HepG2 cells and only necrosis in Hep3B. When a time course was performed for the first 8 h of treatment to elucidate the initial mechanism of cell death responsible for DNA fragmentation, we observed that 5-FU in Hep3B, and cisplatin in both cell lines, induces primary necrosis, whereas at the concentration tested here, paclitaxel clearly triggers apoptosis in both cell lines. HepG2 cells were weakly sensitive to 5-FU in the first 8 h of treatment, so the primary mechanism of cell death was not clear, but results seem to indicate that it could be apoptosis. At 48 h, Bax was not up-regulated with any of the treatments, whereas cisplatin was able to induce Bcl-xL down-regulation in both cell lines. Treatment with 5-FU also down-regulated Bcl-xL in HepG2 cells. We also measured variations in the expression of survivin, an inhibitor of apoptosis that has also been involved in mitototic catastrophe. Hep3B cells seem to show an increase in protein levels with all treatments. Exposure to paclitaxel resulted in the highest effect. In the case of HepG2 cells, there was a decrease in survivin expression when cells were treated with 5FU and paclitaxel, both treatments showing complete loss of the protein. Using an antibody that recognizes unprocessed caspase-3, we observed that the enzyme was assumingly activated in HepG2 cells treated with 5FU and paclitaxel, but only weakly after treatment with cisplatin. Hep3B cells did not show activation since the levels of the pro-enzyme remained the same as that in the control. In conclusion, the three drugs tested in this study could induce cell death, with paclitaxel being more effective inducing apoptosis. 5FU was only effective at high doses and its mechanism seems to be primarily related to necrosis in Hep3B and probably apoptosis in HepG2. Cisplatin mechanism of cell death is probably mediated by the decrease in anti-apoptotic protein Bcl-xL whereas paclitaxel and 5FU are decreasing the apoptosis inhibitor survivin. According to pro-enzyme levels, caspase-3 was only activated in HepG2 cells, whereas in the case of Hep3B cells the mechanisms of toxicity appear to be caspase-3-independent at the time and concentrations tested in this study. The resistance of Hep3B cells to death induced by chemotherapy could be related to an increase in the expression of IAP survivin, which can decrease cell response to the treatment or even switch the type of death from apoptosis to another kind, making therapy less efficient." @default.
• W2011396543 created "2016-06-24" @default.
• W2011396543 creator A5005895518 @default.
• W2011396543 creator A5018018255 @default.
• W2011396543 creator A5045219399 @default.
• W2011396543 creator A5076412201 @default.
• W2011396543 date "2007-07-01" @default.
• W2011396543 modified "2023-10-18" @default.
• W2011396543 title "Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance" @default.
• W2011396543 cites W1964224609 @default.
• W2011396543 cites W1970629830 @default.
• W2011396543 cites W1972896051 @default.
• W2011396543 cites W1974693247 @default.
• W2011396543 cites W1984552603 @default.
• W2011396543 cites W1986752171 @default.
• W2011396543 cites W1993899393 @default.
• W2011396543 cites W2003837981 @default.
• W2011396543 cites W2020516267 @default.
• W2011396543 cites W2032626484 @default.
• W2011396543 cites W2034915619 @default.
• W2011396543 cites W2036214134 @default.
• W2011396543 cites W2048805127 @default.
• W2011396543 cites W2055793916 @default.
• W2011396543 cites W2056616481 @default.
• W2011396543 cites W2062903823 @default.
• W2011396543 cites W2066312401 @default.
• W2011396543 cites W2066441074 @default.
• W2011396543 cites W2067831243 @default.
• W2011396543 cites W2069224110 @default.
• W2011396543 cites W2077087490 @default.
• W2011396543 cites W2082390138 @default.
• W2011396543 cites W2088073262 @default.
• W2011396543 cites W2089461613 @default.
• W2011396543 cites W2092460191 @default.
• W2011396543 cites W2096076005 @default.
• W2011396543 cites W2100495176 @default.
• W2011396543 cites W2103379588 @default.
• W2011396543 cites W2104130860 @default.
• W2011396543 cites W2120714121 @default.
• W2011396543 cites W2125988618 @default.
• W2011396543 cites W2126235126 @default.
• W2011396543 cites W2138509357 @default.
• W2011396543 cites W2148200419 @default.
• W2011396543 cites W2158635250 @default.
• W2011396543 cites W2186790240 @default.
• W2011396543 cites W2313349681 @default.
• W2011396543 doi "https://doi.org/10.1016/j.biopha.2007.02.007" @default.
• W2011396543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17399942" @default.
• W2011396543 hasPublicationYear "2007" @default.
• W2011396543 type Work @default.
• W2011396543 sameAs 2011396543 @default.
• W2011396543 citedByCount "38" @default.
• W2011396543 countsByYear W20113965432012 @default.
• W2011396543 countsByYear W20113965432014 @default.
• W2011396543 countsByYear W20113965432015 @default.
• W2011396543 countsByYear W20113965432017 @default.
• W2011396543 countsByYear W20113965432018 @default.
• W2011396543 countsByYear W20113965432019 @default.
• W2011396543 countsByYear W20113965432020 @default.
• W2011396543 countsByYear W20113965432022 @default.
• W2011396543 crossrefType "journal-article" @default.
• W2011396543 hasAuthorship W2011396543A5005895518 @default.
• W2011396543 hasAuthorship W2011396543A5018018255 @default.
• W2011396543 hasAuthorship W2011396543A5045219399 @default.
• W2011396543 hasAuthorship W2011396543A5076412201 @default.
• W2011396543 hasConcept C109316439 @default.
• W2011396543 hasConcept C1491633281 @default.
• W2011396543 hasConcept C153911025 @default.
• W2011396543 hasConcept C185592680 @default.
• W2011396543 hasConcept C18903297 @default.
• W2011396543 hasConcept C190283241 @default.
• W2011396543 hasConcept C191015642 @default.
• W2011396543 hasConcept C202751555 @default.
• W2011396543 hasConcept C2776694085 @default.
• W2011396543 hasConcept C2777292972 @default.
• W2011396543 hasConcept C2778239845 @default.
• W2011396543 hasConcept C31573885 @default.
• W2011396543 hasConcept C43759708 @default.
• W2011396543 hasConcept C502942594 @default.
• W2011396543 hasConcept C503630168 @default.
• W2011396543 hasConcept C54355233 @default.
• W2011396543 hasConcept C55493867 @default.
• W2011396543 hasConcept C81885089 @default.
• W2011396543 hasConcept C86803240 @default.
• W2011396543 hasConceptScore W2011396543C109316439 @default.
• W2011396543 hasConceptScore W2011396543C1491633281 @default.
• W2011396543 hasConceptScore W2011396543C153911025 @default.
• W2011396543 hasConceptScore W2011396543C185592680 @default.
• W2011396543 hasConceptScore W2011396543C18903297 @default.
• W2011396543 hasConceptScore W2011396543C190283241 @default.
• W2011396543 hasConceptScore W2011396543C191015642 @default.
• W2011396543 hasConceptScore W2011396543C202751555 @default.
• W2011396543 hasConceptScore W2011396543C2776694085 @default.
• W2011396543 hasConceptScore W2011396543C2777292972 @default.
• W2011396543 hasConceptScore W2011396543C2778239845 @default.
• W2011396543 hasConceptScore W2011396543C31573885 @default.
• W2011396543 hasConceptScore W2011396543C43759708 @default.
• W2011396543 hasConceptScore W2011396543C502942594 @default.

• next